Detailed Programme 14-15 September 2008

Monday 15 September
07:00-08:30	SYMP	Satellite Symposium (Fenix I-III) Infectious Diseases Society of Finland, supported by MedImmune
08:45-10:00	PL01	Plenary 1 (Fenix I-III) Keynote lecture by: Dr P. Palese, Mount Sinai School of Medicine, USA: "Genes contributing to the pathogenicity of pandemic influenza viruses" Dr A. Monto, University of Michigan, USA: "Prepandemic vaccines: yes or no?"
10:00-10:30		Coffee break
10:30-12:00	SS01	Scientic Session 1 (Neptuno) Virus host interaction / pathogenesis / transmission Chair: Dr A. Garcia-Sastre, Mount Sinai School of Medicine, USA Co-chair YS: Dr G. Conenello, Mount Sinai School of Medicine, USA Discussants: Dr A. Garcia-Sastre, Mount Sinai School of Medicine, USA: "Interferon antagonist functions of the NS1 protein of influenza virus" Dr Y. Kawaoka, University of Wisconsin School of Veterinary Medicine, USA Dr T. Tumpey, Centers for Disease Control, USA: "Mutations that affect the transmissibility of influenza A viruses" Dr T. Kuiken, Erasmus MC: "Pathology of influenza in humans revisited" Dr G. Conenello, Mount Sinai School of Medecine, USA: "Increased Pathogenesis by influenza A virus expressing a PB1-F2 protein with the N66S mutation: role of CD8+ and CD4+T-cells"
	SS02	Scientific Session 2 (Fenix I-III) Clinical impact & diagnostics approaches Chair: Dr F. Hayden, World Health Organisation, Switzerland Co-chair YS: Dr J. Kovar, University College London, UK Discussants: Dr T. Heikkinen, University of Turku, Finland: "Disease burden and diagnosis of influenza in children" Dr K. Nicholson, University of Leicester, UK: "Burden of influenza and other respiratory viruses in a University Hospital setting at the extremes of life" Dr M. De Jong, The Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam: "Human H5N1 disease: pathogenesis and treatmen" Dr M. Rothberg, Tufts University, USA: "Mortality Benefits of Statins for Pneumonia when Influenza is Circulating"
	SIP01	Science in Practice 1 (Gemini I-III) Increasing the overall epidemic vaccination coverage Chair: Dr A. Monto, University of Michigan, USA Discussants: Dr D. Fedson, France: "Increasing the overall epidemic vaccination coverage: the macroepidemiology of influenza vaccination" Dr T. Szucs, Institute of Social and Preventive Medicine, University of Zurich, Switzerland: "Season Influentza Vaccination in Europe - 2007/08. Coverage Rates in 11 European Countries" Dr K. Nichol, Minneapolis VA Medical Center, USA: "Maximizing seasonal influenza vaccination coverage"
12:00-13:30		Lunch
	SYMP	Satellite Symposium (Gemini I-III) European Vaccine Manufacturers
13:30-15:00	SS03	Scientific Session 3 (Neptuno) Virus structure & replication Chair: Dr R. Lamb, Howard Hughes Medical Institute, USA Co-chair YS: Dr E De Wit, Department of Virology, Erasmus MC, Netherlands Discussants: Dr R. Krug, University of Texas, USA: "Multiple Functions of the NS1 Protein of Influenza A Viruses" Dr Lamb, Howard Hughes Medical Institute, USA: "Influenza Virus Budding" Dr N. Naffakh, Institut Pasteur, France: "Avian influenza A polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection" Dr E.M. Carnero, Mount Sinai School of Medecine, USA: "Nucleotides outside the predicted packaging sequences of the HA segment of influenza A virus influence the incorporation of this segment into virions"
	SS04	Scientific Session 4 (Fenix I-III) Vaccines: current and novel approaches Chair: Dr A. Osterhaus, Erasmus MC, The Netherlands Co-chair YS: John Steel, Mount Sinai School Of Medicine, New York, USA Discussants: Dr M. Tashiro, National Institute of Infectious Diseases, Japan: "The TLR3 agonist, PolyI:PolyC12U, added to Influenza vaccines as a nasal adjuvant induces a wide spectrum cross-protection against different subtypes including highly pathogenic H5N1 avian influenza virus" Dr W. Fiers, Ghent University, Belgium: "A Universal Human Influenza AVaccine" Dr T. Vesikari, University of Tampere Medical School, Finland: "MF59™ Adjuvanted Influenza Vaccine (Fluad©) in Children: Safety and Immunogenicity Following a Second Year Seasonal Vaccination" Dr J.H.C. Kreijtz, Erasmus MC Department of Virology, The Netherlands: "Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques"
	SIP02	Science in Practice 2 (Gemini I-III) Seasonal vaccination of health care workers Chair: Dr T. van Essen, University Medical Center Utrecht, The Netherlands Discussants: Dr R. Jordan, University of Birmingham, UK: "Effectiveness and cost-effectiveness of vaccinating healthcare workers against influenza, and strategies to improve uptake" Dr H. Van Delden, University Medical Center Utrecht, The Netherlands: "Ethics of mandatory vaccination against influenza for health care workers" Dr D. Walter, Robert Koch Institute, Germany: "National influenza immunization campaign – focus on health care workers"
15:00-15:30		Coffee break
15:30-17:00	SS05	Scientific Session 5 (Fenix I-III) Late Breakers Chair: Dr J. Katz, Centers for Disease Control and Prevention, USA Co-Chair YS: Dr A. Lowen, Mount Sinai School of Medicine, USA Discussants: Dr Boettcher, Institute of Virology, Philipps University Marburg, Germany: "Membraneassociated human airway trypsin-like protease (HAT) cleaves the influenza virus hemagglutinin at the cell surface" Richt et al. "Infection of pigs with the human pandemic 1918 influenza virus" Steel et al "Transmisison of influenza in a mammalian host is increased by PB2 627K and 701N" Poster Summary Presentations: Gillard et al. "ASO 3 adjuvanted prepandemic H5N1 vaccine: single dose primary vaccination with clade 1 vaccine strain leads to strong immune responsiveness to clade 2 strain booster vaccination" Hoffenbach (Arnou et al) "Immunogenicity and safety of a novel intradermal influenza vaccine in adult populations" Hancock et al "Effect of priming on subheterotypic antibody responses following vaccination with MF59 adjuvanted H5N1 vaccine."
	SS06	Scientific Session 6 (Neptuno) How to evaluate vaccine efectiveness? Chair: Dr A. Monto, University of Michigan, USA Speakers: Dr L. Simonsen, National Institutes of Health, USA: "Influenza Vaccination and Mortality Benefits: New Insights, New Opportunities" Dr K. Nichol, Minneapolis VA Medical Center, USA: "Challenges in evaluating influenza effectiveness" Dr E. Hak, University Medical Center Utrecht, Netherlands: "Impact of influenza vaccination on mortatlity risk among the elderly: methodological inquiry"
	SIP03	Science in Practice 3 (Gemini I-III) Epidemic and pandemic use of antivirals Chair: Dr F. Hayden, World Health Organisation, Switzerland Discussants: Dr N. Ferguson, University of London, UK: "Antiviral use in a pandemic: predicting impact and the risk of resistance" Dr J. Van-Tam, University of Nottingham, UK Dr F. Hayden, World Health Organisation, Switzerland: "Antivirals for Seasonal, A(H5N1), and Pandemic Influenza: Efficacy, Resistance, and New Agents"
17:00-18:00		Poster Session 1 (Blue Corner)
18:00-19:30	SYMP	Satellite Symposium (Fenix I-III) F. Hoffmann-La Roche